Recent decisions at the FDA threaten to turn its disagreements with the drugmaker UniQure into another political headache for ...
China has approved a new obesity treatment from Pfizer, heightening competition in a market poised to become even more crowded ...
A federal appeals court will hear arguments Friday in the Trump administration's effort to subpoena patient records on gender ...
In this week’s STATus Report, host Alex Hogan explains why weight loss pills were so much harder to develop than injectables.
Servier said it would buy Day One Biopharmaceuticals, the maker of a drug for childhood brain tumors, in a deal worth roughly $2.5 billion.
Immediately after U.S. health officials linked Tylenol to autism, the drug's use in pregnant women visiting ERs dropped, new ...
Stand Up For Science has become a formal organization and adopted a new strategy that's more confrontational with grassroots ...
The named families, as administrators of private rural Amish schools, are challenging $118,000 in state fines for not ...
Meanwhile, Moderna is trying to reset its future around oncology.
Virtual chronic care company Omada, which went public less than a year ago, reported a quarterly profit for the first time.
Science Corp. raised $230 million as it awaits a decision from the FDA on PRIMA, their wireless retinal implant.
The DOJ's fight against gender-affirming care, the impact of Trump's 'Don't take Tylenol,' and more health news ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results